coronary restenosis
Information
- Disease name
- coronary restenosis
- Disease ID
- DOID:4247
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04475380 | Active, not recruiting | Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents | September 21, 2018 | April 30, 2025 | |
| NCT04915391 | Active, not recruiting | Restenosis in Coronary Stents And Cutaneous HEaLing | April 25, 2017 | April 30, 2023 | |
| NCT00124943 | Completed | Phase 1/Phase 2 | Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis | July 2005 | August 2009 |
| NCT00140101 | Completed | Phase 2 | Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries | May 2005 | January 2012 |
| NCT00148356 | Completed | Phase 2/Phase 3 | Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries | September 2004 | October 2010 |
| NCT00162357 | Completed | Phase 4 | Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty | April 2004 | December 2005 |
| NCT00180310 | Completed | Phase 3 | SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System | July 2005 | February 2011 |
| NCT00180466 | Completed | PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions | October 2004 | July 2009 | |
| NCT00248066 | Completed | Phase 2 | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries | September 2005 | |
| NCT00287573 | Completed | Phase 2/Phase 3 | Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis | June 2003 | January 2010 |
| NCT00300131 | Completed | ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation | March 2006 | July 2011 | |
| NCT00402272 | Completed | Phase 4 | SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe | November 2006 | June 2010 |
| NCT00409981 | Completed | Phase 1/Phase 2 | Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II) | July 2004 | June 2006 |
| NCT00412126 | Completed | N/A | Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI | July 2002 | September 2005 |
| NCT02263313 | Completed | EGO-COMBO Clinical End-point Extension Study Beyond 36 Months | September 2014 | September 2014 | |
| NCT00106587 | Completed | Phase 1/Phase 2 | Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I) | December 2003 | March 2012 |
| NCT01249027 | Completed | XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study | November 2010 | January 2017 | |
| NCT01262703 | Completed | N/A | Safety Study of a Bioresorbable Coronary Stent | December 2011 | December 2018 |
| NCT01269242 | Completed | Phase 2 | The Effects of Bindarit in Preventing Stent Restenosis | January 2009 | April 2011 |
| NCT01274234 | Completed | Phase 1/Phase 2 | OCT Evaluation of Healing of COMBO Stent | October 2010 | June 2012 |
| NCT01331707 | Completed | Phase 4 | DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population | November 2010 | December 2013 |
| NCT01583608 | Completed | ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease | April 2012 | June 2016 | |
| NCT01651390 | Completed | N/A | Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis. | June 2012 | July 2016 |
| NCT01674803 | Completed | N/A | Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT) | December 21, 2012 | August 25, 2020 |
| NCT01759290 | Completed | ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients. | January 2013 | December 2015 | |
| NCT01894152 | Completed | XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study | July 2013 | October 9, 2019 | |
| NCT01977534 | Completed | To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels | January 2014 | October 2018 | |
| NCT02151812 | Completed | N/A | Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) | August 13, 2014 | October 28, 2019 |
| NCT00055510 | Completed | Phase 2/Phase 3 | A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. | ||
| NCT02367495 | Completed | N/A | Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES | January 2015 | October 25, 2017 |
| NCT02944890 | Completed | N/A | Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis | May 2016 | May 2019 |
| NCT03242096 | Completed | N/A | Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon | July 21, 2017 | January 31, 2021 |
| NCT03667313 | Completed | Phase 3 | Treatment of In-Stent Restenosis 2 Study | October 1, 2018 | December 31, 2021 |
| NCT00552669 | Completed | Phase 4 | Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents | January 2006 | September 2007 |
| NCT00589810 | Completed | Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal | August 2007 | November 2011 | |
| NCT00631228 | Completed | XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study | June 2008 | August 2012 | |
| NCT00714545 | Completed | Phase 4 | SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents | April 2006 | November 2013 |
| NCT00714623 | Completed | The SCRIPPS DES REAL WORLD Registry | March 2005 | April 2012 | |
| NCT00752362 | Completed | Phase 4 | Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT) | March 2006 | |
| NCT00856856 | Completed | N/A | ABSORB Clinical Investigation, Cohort B | March 2009 | March 2016 |
| NCT00859183 | Completed | Phase 4 | Oral Sirolimus for In-Stent Restenosis | October 2001 | March 2004 |
| NCT00882219 | Completed | Phase 3 | Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period | March 2009 | July 2012 |
| NCT00916370 | Completed | Phase 3 | SPIRIT PRIME Clinical Trial | June 2009 | February 2014 |
| NCT01023789 | Completed | N/A | ABSORB EXTEND Clinical Investigation | January 2010 | October 2016 |
| NCT01066650 | Completed | Phase 4 | The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente | June 2008 | September 2012 |
| NCT01086228 | Completed | XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan | March 2010 | August 2016 | |
| NCT01106534 | Completed | Phase 4 | XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort | August 2009 | July 2015 |
| NCT01115933 | Completed | N/A | A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population | April 2010 | December 2013 |
| NCT01120379 | Completed | XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) | July 2008 | December 2013 | |
| NCT01171820 | Completed | Phase 4 | SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study) | November 2006 | July 2010 |
| NCT01178268 | Completed | Phase 4 | XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) | August 2010 | September 2014 |
| NCT01205776 | Completed | N/A | EXCEL Clinical Trial | September 29, 2010 | June 28, 2019 |
| NCT01205789 | Completed | EXCEL Clinical Trial (Universal Registry) | October 2010 | September 2012 | |
| NCT06075602 | Recruiting | COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease | November 1, 2021 | December 31, 2031 | |
| NCT04988685 | Recruiting | SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters | June 1, 2021 | December 31, 2031 | |
| NCT05089864 | Recruiting | N/A | STAR and Deferred Stenting Study | November 23, 2021 | December 30, 2025 |
| NCT04280029 | Recruiting | N/A | SELUTION SLR™ 014 In-stent Restenosis | July 6, 2020 | November 2027 |
| NCT05471245 | Recruiting | N/A | AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease | May 23, 2023 | August 31, 2025 |
| NCT02474485 | Suspended | N/A | Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR | March 2015 | June 2021 |
| NCT00243308 | Terminated | Phase 2 | Serp-1 for the Treatment of Acute Coronary Syndrome | October 2005 | December 2008 |
| NCT01967199 | Terminated | Phase 4 | Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis | April 18, 2013 | February 14, 2017 |
| NCT02300454 | Unknown status | Phase 4 | Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions | June 2015 | April 2019 |
| NCT00500279 | Unknown status | Phase 4 | Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial | November 2006 | October 2009 |
| NCT01915420 | Unknown status | The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions | August 2013 | August 2017 | |
| NCT00376870 | Unknown status | Phase 3 | PIoglitazone for PrEvention of Restenosis in Diabetic Patients | July 2008 | April 2011 |
| NCT04494750 | Unknown status | Physiology and Residual Ischemia After Percutaneous Coronary Intervention | February 18, 2021 | December 2023 | |
| NCT02175706 | Unknown status | N/A | DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity | November 2010 | June 2017 |
| NCT00426049 | Unknown status | Phase 3 | Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation | October 2006 | |
| NCT02508714 | Unknown status | N/A | Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents | October 7, 2016 | March 2019 |
| NCT03074305 | Withdrawn | N/A | DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold | March 8, 2017 | January 25, 2018 |
- Disase is a (Disease Ontology)
- DOID:4248
- Cross Reference ID (Disease Ontology)
- MESH:D023903
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0948480
- MeSH unique ID (MeSH (Medical Subject Headings))
- D023903